Startups
Glycomine
Glycomine is a clinical-stage biotechnology company developing replacement therapies for serious rare genetic diseases. Its platform delivers substrates, enzymes or proteins into relevant cells to bypass disrupted biochemical pathways. Its lead investigational medicine, GLM101, delivers mannose-1-phosphate to address the metabolic defect in PMM2-congenital disorder of glycosylation, a multisystem disease with neurological symptoms including ataxia. The company completed enrollment in its global randomized Phase 2b POLAR study in April 2026. Glycomine is based in San Carlos, California.
Team
Arthur PappasBoard Director |
Chris StarrScientific and Clinical Advisory Board Member |
 Dominic SchmidtBoard Director |
Donna Roy GroganScientific and Clinical Advisory Board Member |
Geoffrey HirdChief Technology Officer |
Hicham AlaouiChief Scientific Officer |
Howard MayerScientific and Clinical Advisory Board Member |
 Jason P. HaflerBoard Director |
Jayson PunwaniBoard Director |
Jim TrenkleBoard Director |
Joshua GrassBoard Chairperson |
Kenneth HarrisonBoard Director |
 Niall O’DonnellBoard Director |
Peter McWilliamsChief Business Officer |
Rose MarinoChief Medical Officer |
Steven AxonChief Executive Officer and Board Director |
Susan PerlmanScientific and Clinical Advisory Board Member |
Youssef BennaniBoard Director |